Lobe Sciences Ltd. (LOBE.CN) Research

Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.

Market snapshot

Symbol
LOBE.CN
Price
$0.08
Day change
0.00%
Market cap
$15.5M
P/E ratio
-3.83x
52-week range
0.03-0.18
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 6 months

Peer companies

  • AI/ML Innovations Inc. (AIML.CN)
  • Avant Brands Inc. (AVNT.TO)
  • Ayurcann Holdings Corp. (AYUR.CN)
  • Blueberries Medical Corp. (BBM.CN)
  • CLS Holdings USA, Inc. (CLSH.CN)
  • Crescita Therapeutics Inc. (CTX.TO)
  • Delivra Health Brands Inc. (DHB.V)
  • Mydecine Innovations Group Inc. (MYCO.NE)

Open Lobe Sciences Ltd. (LOBE.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.